Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMyung-Won LeeInje University Busan Paik HospitalSJSeong Hyun JeongAjou UniversityKKKa‐Won KangKorea University

Discussion

Loading...

Member takes

Implication

Phase II study finds high response rates with R-CHOP including lenalidomide, indicating potential for improved CNS prophylaxis in DLBCL patients.

Key Points

  • Lenalidomide with R-CHOP yielded an overall response rate of 96.6% in high-risk DLBCL patients.
  • After 15.4 months follow-up, the progression-free survival rate was 73.5%, highlighting effective CNS prophylaxis.
  • Patients receiving the combination reported neutropenia as the most common adverse event, at 17%.
  • The study supports R-CHOP's use in preventing CNS relapse, though further follow-up is required.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d638https://doi.org/10.1182/blood-2025-1915
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lenalidomide–rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach2025 · 1 citations
  2. 2Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)2025 · 2 citations
  3. 3Safety and feasibility of high dose methotrexate addition to R-CHOP chemotherapy for prophylaxis and treatment of secondary cns involvement by large B-cell lymphoma in a community-based hospital setting2025
  4. 4Impact of primary CNS prophylaxis in high CNS-IPI DLBCL: Analysis from the czech national lymphoma registry2025
  5. 5Impact of high-dose methotrexate in both central nervous system relapse and systemic progression in high-risk DLBCL: A retrospective analysis of a brazilian cohort2025